Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans
Hormone Therapy and Angiotensin-Dependent Arterial and Renal
University of Calgary
200 participants
Nov 30, 2020
OBSERVATIONAL
Conditions
Summary
1. to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women. 2. to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.
Eligibility
Inclusion Criteria2
- Age 18 to 90 years
- Taking hormones orally or non-orally (either estrogen, progesterone or testosterone)
Exclusion Criteria8
- Cardiovascular disease (symptoms consistent with myocardial ischemia, previously documented myocardial ischemia, cardiac arrhythmias or valve abnormalities, or abnormal ECG at screening)
- Cerebrovascular disease (transient ischemic attacks or stroke)
- History of hypertension (BP>140/90 or use of antihypertensive medications)
- Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2
- Diabetes mellitus (defined by history, use of hypoglycaemic agents or a fasting glucose >7mmol/L)
- Current smoker
- Previous history of preeclampsia
- Anabolic steroids, cortical steroids, or non-steroidal anti-inflammatory medications, or at the discretion of the investigator.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Captorpril challenge to each participant
Iohexol infusion to evaluate measured GFR
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05442463